Bone metastases

Supportive Care in Cancer: A Handbook for Oncologists

Volumn , Issue , 1999, Pages 453-481

  Body, J J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001941381     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (97)

1. Galasko CSB. Skeletal metastases. Clin Orthop Rel Res 1986; 210:18-30.
2. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55:61-66.
3. Kamby C, Vejborg I, Daugaard S, Guldhammer B, Dirksen H, Rossing N, Mouridsen HT. Clinical and radiologic characteristics of bone metastases in breast cancer. Cancer 1987; 60:2524-2531.
4. Bhardwaj S, Holland JF. Chemotherapy of metastatic cancer in bone. Clin Orthop Rel Res 1982; 169:28-37.
5. Elte JWF, Bijvoet OLM, Cleton FJ, van Oosterom A, Sleeboom HP. Osteolytic bone metastases in breast carcinoma: pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol 1986; 22:493-500.
6. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1-18.
7. Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med 1986; 81:381-386.
8. Yamashita K, Koyama H, Inaji H. Prognostic significance of bone metastasis from breast cancer. Clin Orthop Rel Res 1995; 312:89-94.
9. Yamashita K, Denno K, Ueda T, Komatsubara Y, Kotake T, Usami M, Maeda O, Nakano SI, Hasegawa Y. Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer 1993; 71:1297-1302.
10. Body JJ. Metastatic bone disease: clinical and therapeutic aspects. Bone 1992; 13: S57-S62.
11. Pecherstorfer M, Vesely M. Diagnosis and monitoring of bone metastases. In: Body JJ, ed. Tumor Bone Diseases and Osteoporosis in Cancer Patients. New York: Marcel Dekker. In press.
12. Grossman SA, Sheidler VR, McGuire DB, Geer C, Santor D, Piantadosi S. A comparison of the Hopkins Pain Rating Instrument with standard visual analogue and verbal descriptor scales in patients with cancer pain. J Pain Symptom Manage 1992; 7:196-203.
13. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334:488-493.
14. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335:1785-1791.
15. Thrall JH, Ellis BI. Skeletal metastases. Radiol Clin North Am 1987; 25:1155-1170.
16. Gold RI, Seeger LL, Bassett LW, Steckel RJ. An integrated approach to the evaluation of metastatic bone disease. Radiol Clin North Am 1990; 28:471-483.
17. Jacobson AF, Cronin EB, Stomper PC, Kaplan WD. Bone scans with one or two new abnormalities in cancer patients with no known metastases: frequency and serial scintigraphic behavior of benign and malignant lesions. Radiology 1990; 175:229-232.
18. Rosselli del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V, for the National Research Council Project on Breast Cancer Follow-up. Intensive diagnostic follow-up after treatment of primary breast cancer. JAMA 1994; 271:1593-1597.
19. Coleman RE, Mashiter G, Fogelman I, Rubens RD. Osteocalcin: a marker of metastatic bone disease. Eur J Cancer 1988; 24:1211-1217.
20. Redmond J III, Spring DB, Munderloh SH, George CB, Mansour RP, Volk SA. Spinal computed tomography scanning in the evaluation of metastatic disease. Cancer 1984; 54:253-258.
21. Jones AL, Williams MP, Powles TJ, Oliff JFC, Hardy JR, Cherryman G, Husband J. Magnetic resonance imaging in the detection of skeletal metastases in patients with breast cancer. Br J Cancer 1990; 62:296-298.
22. Haukaas S, Roervik J, Halvorsen OJ, Foelling M. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br J Urol 1997; 79:770-776.
23. Bombardieri E, Pizzichetta M, Veronesi P, Seregni E, Bogni A, Maffioli L, Jotti GS, Bassetto MA, Zurrida S, Costa A. CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases. Eur J Cancer 1992; 29:144-146.
24. Iwase H, Kobayashi S, Itoh Y, Fukuoka H, Kuzushima T, Iwata H, Yamashita T, Kaitoh A, Ithoh K, Masaoka A. Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. Br Cancer Res Treat 1994; 33:83-88.
25. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Gimenez N, Pahisa J, Velasco M, Ballesta AM. Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients. Br Cancer Res Treat 1995; 36:41-48.
26. Tomlinson IPM, Whyman A, Barrett JA, Kremer JK. Tumour marker CA 15-3: possible uses in the routine management of breast cancer. Eur J Cancer 1995; 31A: 899-902.
27. Crippa F, Bombardieri E, Seregni E, Castellani MR, Gasparini M, Maffioli L, Pizzichetta M, Buraggi GL. Single determination of CA 15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer. J Nucl Biol Med 1992; 36:52-55.
28. Aydiner A, Topuz E, Disci R, Yasasever V, Dincer M, Dincol K, Bilge N. Serum tumor markers for detection of bone metastasis in breast cancer patients. Acta Oncol 1994; 33:181-186.
29. Safi F, Kohler I, Rottinger E, Beger H. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 1991; 68:574-582.
30. Price CP, Milligan TP, Darte C. Direct comparison of performance characteristics of two immunoassays for bone isoform of alkaline phosphatase in serum. Clin Chem 1997; 43:2052-2057.
31. Pecherstorfer M, Zimmer-Roth I, Schilling T, Woitge HW, Schmidt H, Baumgartner G, Thiebaud D, Ludwig H, Seibel MJ. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 1995; 80:97-103.
32. Body JJ, Delmas PD. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 1992; 74:471-475.
33. Body JJ, Dumon JC, Blocklet D, Darte C. The bone isoenzyme of alkaline phosphatase in hypercalcaemic patients. Eur J Cancer 1997; 33:1578-1582.
34. Marchei P, Santini D, Bianco V, Chiodini S, Reale MG, Simeoni F, Marchei GG, Vecchione A. Serum ostase in the follow-up of breast cancer patients. Anticancer Res 1995; 15:2217-2222.
35. Zaninotto M, Secchiero S, Rubin D. Serum bone alkaline phosphatase in the followup of skeletal metastases. Anticancer Res 1995; 15:2223-2228.
36. Wolff JM, Ittel T, Boeckmann W, Reinike T, Habib FK, Jakse G. Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer. Eur Urol 1996; 30:302-306.
37. Body JJ, Cleeren A, Pot M, Borkowski A. Serum osteocalcin (BGP) in tumor-associated hypercalcemia. J Bone Miner Res 1986; 1:523-527.
38. Kamby C, Egsmose C, Sölétormos G, Dombernowsky P. The diagnostic and prognostic value of serum bone GLA protein (osteocalcin) in patients with recurrent breast cancer. Scand J Clin Lab Invest 1993; 53:439-446.
39. Shih WJ, Wierzbinski B, Collins J, Magoun S, Chen IW, Ryo UY. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements. J Nucl Med 1990; 31: 1486-1489.
40. Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 1996; 22:289-331.
41. Lipton A, Demers L, Daniloff Y, Curley E, Hamilton C, Harvey H, Witters L, Seaman J, Van der Giessen R, Seyedin S. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem 1993; 39:614-618.
42. Body JJ, Dumon JC, Gineyts E, Delmas PD. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 1997; 75:408-412.
43. Coleman RE, Whitaker KD, Moss DW, Mashiter G, Fogelman I, Rubens RD. Biochemical monitoring predicts response in bone to systemic treatment. Br J Cancer 1988; 58:205-210.
44. Cooper EH, Forbes MA, Hancock AK, Parker D, Laurence V. Serum bone alkaline phosphatase and CA 549 in breast cancer with bone metastases. Biomed Pharmacother 1992; 46:31-36.
45. Cooper EH, Whelan P, Purves D. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. Prostate 1994; 25:236-242.
46. Williams AT, Shearer MJ, Oyeyi J, Aitchison RG, Newland AC, Schey SA. Serum osteocalcin in the management of myeloma. Eur J Cancer 1992; 29A:140-142.
47. Coleman RE. Monitoring of bone metastases. Eur J Cancer 1998; 34:252-259.
48. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman R. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 1997; 15:131-138.
49. Vinholes JJF, Purohit OP, Abbey ME, Eastell R, Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8:1243-1250.
50. Mundy GR. Mechanisms of bone metastasis. Cancer 1997; 80:1546-1556.
51. Body JJ, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev 1996; 22:265-287.
52. Taube T, Elomaa I, Blomqvist C, Beneton MNC, Kanis JA. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 1994; 15:161-166.
53. Siwek B, Lacroix M, de Pollak C, Marie P, Body JJ. Secretory products of breast cancer cells affect human osteoblastic cells: partial characterization of active factors. J Bone Miner Res 1997; 12:552-560.
54. Vargas SJ, Gillespie MT, Powell GJ, Southby J, Danks JA, Moseley JM, Martin TJ. Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization. J Bone Miner Res 1992; 7: 971-979.
55. Goltzman D, Rabbani SA. Pathogenesis of osteoblastic metastases. In: Body JJ, ed. Tumor Bone Diseases and Osteoporosis in Cancer Patients. New York: Marcel Dekker. In press.
56. Barillé S, Collette M, Bataille R, Amiot M. Myeloma cells upregulate interleukin- 6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995; 86:3151-3159.
57. Twycross RG. Management of pain in skeletal metastases. Clin Orthop Rel Res 1995; 312:187-196.
58. Eisenberg E, Berkey CS, Carr DB, Mosteller F, Chalmers TC. Efficacy and safetyof nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994; 12:2756-2765.
59. Hayes DF, Henderson IC, Shapiro CL. Treatment of metastatic breast cancer: present and future prospects. Semin Oncol 1995; 22:5-19.
60. Small EJ, Vogelzang NJ. Second line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997; 15:382-388.
61. Gainor BJ, Buchert P. Fracture healing in metastatic bone disease. Clin Orthop Rel Res 1983; 178:297-302.
62. Hipp JA, Springfield DS, Hayes WC. Predicting pathologic fracture risk in the management of metastatic bone defects. Clin Orthop Rel Res 1995; 312:120-135.
63. Aaron AD. The management of cancer metastatic to bone. JAMA 1994; 272:1206-1209.
64. Bunting RW. Rehabilitation of cancer patients with skeletal metastases. Clin Orthop Rel Res 1995; 312:197-200.
65. Poulsen HS, Nielsen OS, Klee M, Rørth M. Palliative irradiation of bone metastases. Cancer Treat Rev 1989; 16:41-48.
66. Hoskin PJ. Radiotherapy in the management of bone pain. Clin Orthop Rel Res 1995; 312:105-119.
67. Rasmusson B, Vejborg I, Jensen AB, Andersson M, Banning AM, Hoffmann T, Pfeiffer P, Nielsen HK, Sjøgren P. Irradiation of bone metastases in breast cancer patients: a randomized study with 1 year follow-up. Radiother Oncol 1995; 34:179-184.
68. Bates T, Yarnold JR, Blitzer P, Nelson OS, Rubin P, Maher J. Bone metastasis consensus statement. Int J Radiation Oncol Biol Phys 1992; 23:215-216.
69. Robinson RG, Preston DF, Spicer JA, Baxter KG. Radionuclide therapy of intractable bone pain: emphasis on strontium-89. Semin Nucl Med 1992; 22:28-32.
70. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA. A prospective randomised double blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27:954-958.
71. Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, Crook J, Gulenchyn KY, Hong KE, Wesolowski C, Yardley J. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiation Oncol Biol Phys 1993; 25:805-813.
72. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, Reed NSE, Russell JM, Yardley J. A comparison of the palliative effects of strontium- 89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31:33-40.
73. Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995; 274:420-424.
74. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, Livingston RB, Gordon EE, Chapman CR, Appelbaum FR. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993; 34:1839-1844.
75. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier DB, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16:1547-1581.
76. Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Straub RF, Cabahug CJ, Weber DA, Wong CTC, Sacker DF, Madajewicz S, Park TL, Meek AG. Biodistribution of Sn-117m(4+) DTPA for palliative therapy of painful osseous metastases. Radiology 1993; 186:279-283.
77. Zimolo Z, Wesolowski G, Rodan GA. Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J Clin Invest 1995; 96:2277-2283.
78. Vitté C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996; 137:2324-2333.
79. Grill V, Ho P, Body JJ, Johanson N, Lee SC, Kukreja SC, Moseley JM, Martin TJ. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 1991; 73:1309-1315.
80. Singer FR, Ritch PS, Lad TE, Ringenberg QS, Schiller JH, Recker RR, Ryzen E. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. Arch Intern Med 1991; 151:471-476.
81. O’Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D, Kanis JA. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 1993; 67:560-563.
82. Harinck HIJ, Bijvoet OLM, Plantingh AST, Body JJ, Elte JWF, Sleeboom HP; Wildiers J, Neijt JP. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. AmJMed 1993; 82:1133-1142.
83. Body JJ, Dumon JC. Treatment of tumor-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of the tumour type. Ann Oncol 1994; 5:359-363.
84. Walls J, Ratcliffe WA, Howell A, Bundred NJ. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer 1994; 70:169-172.
85. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. A randomised double- blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995; 72:1289-1293.
86. Ralston SH, Thiébaud D, Herrmann Z, Steinhauer EU, Thurlimann B, Walls J, Lichinitser MR, Rizzoli R, Hagberg H, Huss HJ, Tubiana-Hulin M, Body JJ. Doseresponse study of ibandronate in treatment of cancer-associated hypercalcaemia. Br J Cancer 1997; 75:295-300.
87. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13:2427-2430.
88. Ernst DS, Brasher P, Hagen N, Paterson AH, MacDonald RN, Bruera E. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 1997; 13:319-326.
89. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Doubleblind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11:59-65.
90. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. J Clin Oncol 1996; 14:2552-2559.
91. Lipton A. Bisphosphonate treatment of lytic bone metatases. ASCO Educational Book 1998:94-99.
92. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ for the Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998; 16: 2038-2044.
93. Kanis JA, Powles T, Paterson AHG, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996; 19: 663-667.
94. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-363.
95. McCloskey EV, MacLennan ICM, Drayson M, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Hematol 1998; 100:317-325.
96. Berenson JR, Lichtenstein A, Porter L, Dimopoulous A, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD for the Myeloma Aredia Study Group. Longterm pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16:593-602.
97. Bataille R. Management of myeloma with bisphosphonates. N Engl J Med 1996; 334:529-530.